Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Needham Maintains Buy on Intercept Pharmaceuticals, Raises Price Target to $26

Needham analyst Joseph Stringer maintains Intercept Pharmaceuticals (NASDAQ:ICPT) with a Buy and raises the price target from $22 to $26.
byBenzinga Newsdesk
March 3, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

Needham analyst Joseph Stringer maintains Intercept Pharmaceuticals (NASDAQ:ICPT) with a Buy and raises the price target from $22 to $26.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0